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orBackground: Photosensitivity (PS) in lupus erythematosus (LE) is frequently determined by patient report.Objective: We sought to characterize self-reported PS in cutaneous LE (CLE).Methods: The PS survey was used to classify subject responses into 5 phenotypes: direct sun-induced CLE
flare (directCLE); general exacerbation of CLE (genCLE); polymorphic light eruptionelike reactions
(genSkin); general pruritus/paresthesias (genRxn); and sun-induced systemic symptoms (genSys). In all, 91
subjects with CLE alone or with CLE and systemic LE were interviewed.Results: In all, 81% ascribed to 1 or more PS phenotypes. CLE-specific reactions (direct sun-induced
CLE flare or general exacerbation of CLE) were reported by 86% of photosensitive subjects. Higher CLE
disease activity (measured by CLE Disease Area and Severity Index activity scores) was suggestive of
direct sun-induced CLE flare reactions (P = .09). In all, 60% of photosensitive subjects described CLE-
nonspecific reactions: polymorphic light eruptionelike rash and general pruritus/paresthesias. These
phenotypes often co-occurred with CLE-specific reactions and were predicted by more systemic
disease activity as measured by Physicians Global Assessment (PGA) scores in regression analyses
(genSkin, P = .02) and (genRxn, P = .05). In all, 36% of subjects reported systemic reactions and higher
PGA scores were predictive of the sun-induced systemic symptoms phenotype (P = .02); a diagnosis of
systemic LE was not (P = .14).Limitations: PS was inferred from patient report and not directly observed.Conclusions: Characterization of self-reported PS in LE reveals that patients experience combinations of
CLE-specific, CLE-nonspecific, and systemic reactions to sunlight. Sun-induced CLE flares are associated
with more active CLE disease. Polymorphic light eruptionelike, generalized pruritus/paresthesias, and
systemic reactions are associated with more active systemic disease. Recognition of PS phenotypes will
permit improved definitions of clinical PS and allow for more precise investigation into its pathophysi-
ology. ( J Am Acad Dermatol 2013;69:205-13.)
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hotosensitivity (PS) is one of the most com-
mon manifestations of systemic lupus eryth-
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206 Foering et alAlthough investigations into PS in LE have fo-
cused predominantly on cutaneous LE (CLE) induc-
tion via phototesting,3-6 most patients with LE do not
undergo phototesting as part of their clinical
workup. More commonly, clinicians apply the PS
criterion to patients with LE based on patient history
and/or physical examination findings related to sun-CAPSULE SUMMARY
d According to the American College of
Rheumatology, photosensitivity in lupus
erythematosus (LE) is determined by
clinical examination or by patient history
of unusual reaction to sunlight.
d Self-reported photosensitivity in
cutaneous LE comprises cutaneous
LE-specific and LE-nonspecific skin
reactions, pruritus/paresthesias, and
systemic symptoms.
d Physicians should recognize the varied
manifestations of photosensitivity in LE
because these phenotypes are
associated with both systemic and
cutaneous disease activity.induced eruptions.2 Making
the diagnosis of PS in LE is
simple when patients report
a history of LE exacerbation
in the summer or after a
tropical holiday. Most pa-
tients, however, describe a
wide array of adverse reac-
tions to sunlight, some of
which may be related to LE
and others not.7-9
On the differential diagno-
sis for CLE is the most com-
mon of all photodermatoses:
polymorphic light eruption
(PMLE). Early lesions of
CLE may be difficult to
distinguish from PMLE,10-13
both clinically and histologi-
cally. Furthermore, PMLE has
been reported to occur more
frequently in patients with LE than in the general
population.14,15 Despite these associations, studies
have failed to showany convincing pathophysiologic
link between PMLE and LE,16-19 which suggests
that the 2 conditions are comorbid. An alternative
explanation is that PS in LE is variable and that a
PMLE-like reaction may be one of many clinical
phenotypes of PS in LE.
In our tertiary referral population, we found that
70% of patients with CLE reported adverse reactions
to sunlight.20 Patients’ descriptions of PS varied from
CLE induction after sun exposure to generalized rash
to PMLE-like reactions. The purpose of this study
was to characterize clinical PS phenotypes among a
primarily CLE population. A secondary objective was
to examine skin histology among PS phenotypes in
LE and evaluate whether differences in cell type/
count play a role in the pathophysiology of various
PS phenotypes.
METHODS
Subject selection
Patients with LE presenting to the outpatient auto-
immune skin disease clinic at the University of
Pennsylvania were enrolled in an ongoing database
study of prevalence and severity of LE. All patients
older than 18 years with clinical, histologic, and/orserologic evidence of CLE and/or SLE with skin
manifestations were invited to participate. Subjects
were categorized according to the modified Gilliam
classification into the various subtypes of CLE.21
Subjects with SLE who met the American College of
Rheumatology criteria2 were included if they also
had a form of CLE. The protocol for the study wasapproved by the institu-
tional review board of the
University of Pennsylvania
School of Medicine.
Study procedures
Study visits were com-
pleted at the time of subjects’
regularly scheduled clinic
visit. Information was ob-
tained by clinical interview,
physical examination, medi-
cal record review, and subject
questionnaires. A complete
skin examination was per-
formed and the CLE Disease
Area and Severity Index
(CLASI) outcome measure
was completed. Whenever
available, recent laboratory
values, including LE serol-ogies and/or biopsy results, were reviewed and
documented in the study chart.
Clinical interview using the PS survey
The PS survey provided a framework for charac-
terizing subjects’ experience of sun sensitivity or lack
thereof (Fig 1). The PS survey was based on infor-
mation gathered over 9 months, during which pa-
tients in the autoimmune skin disease clinic were
interviewed about their experience with sunlight.
Recurring themes of self-reported PSerelating to
sun-induced reactions, morphology, characteristics,
and timingewere identified and incorporated into a
brief PS survey.
Subjects were instructed to ‘‘Tell me about what
happens when you go in the sun.’’ Study personnel
completed the PS survey using the subject’s free-form
answer. Only after the subject was allowed to speak
freely did study personnel ask questions from the PS
survey to limit information bias. Any adverse reaction
to sunlight described by the subject was accounted
for and classified into a PSphenotype.Data collection
took place from November 2009 to January 2011.
PS phenotypes
Subject-reported adverse reactions to sunlight
were classified into 1 of 5 categories based on
Abbreviations used:
CLASI: Cutaneous Lupus Erythematosus
Disease Area and Severity Index
CLE: cutaneous lupus erythematosus
directCLE: direct sun-induced cutaneous lupus
erythematosus flare
genCLE: general exacerbation of cutaneous
lupus erythematosus
genRxn: general pruritus/paresthesias
genSkin: polymorphic light eruption-like
genSys: sun-induced systemic symptoms
LE: lupus erythematosus
mDC: myeloid dendritic cells
PGA: Physicians Global Assessment
PMLE: polymorphic light eruption
PS: photosensitivity
SELENA: Safety of Estrogens in Lupus
Erythematosus National Assessment
SLE: systemic lupus erythematosus
SLEDAI: Systemic Lupus Erythematosus Disease
Activity Index
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4 corresponded with direct sun-induced CLE flare
(directCLE), question 3 with general exacerbation
of CLE (genCLE), question 5 with genSkin, ques-
tions 6 and 7 with general pruritus/paresthesias
(genRxn), and question 8 with sun-induced sys-
temic symptoms (genSys). If a subject’s report did
not correspond with the answer options provided,
the study personnel could write answers in the
blanks provided. This occurred almost exclusively
for the genCLE phenotype. Thus, subjects reporting
‘‘yes’’ to question 3 or those necessitating a write-in
answer, suggestive of a link between CLE and sun
exposure, were classified as the genCLE phenotype.
Finally, the directCLE and genCLE phenotypes were
mutually exclusive, but all other PS phenotypes
were not and patients could be classified as multi-
ple PS phenotype.
Timing of PS reactions
Timing of 3 PS phenotypes was ascertained for:
directCLE, genSkin, and genRxn. Subjects were
asked about onset of reactions and time until reso-
lution of cutaneous reactions after sun exposure.
Reactions were labeled early, transient; early, lasting;
or late, lasting (Table II).
SLE Disease Activity Index
Disease activity in SLE was assessed by the
Safety of Estrogens in LE National Assessment
(SELENA)eSLE Disease Activity Index (SLEDAI), a
validated instrument used in the SELENA trials.22 This
SLEDAI uses a weighting system to evaluate disease
activity in 9 organ systems. The total SLEDAI score
ranges from 0 (no activity) to 105 (maximumactivity). Overall systemic disease activity is further
assessed by the clinician via the Physicians Global
Assessment (PGA) score, a 0-to-3 scale with 0 = none
to 3 = severe systemic disease activity.
CLE Disease Area and Severity Index
The CLASI is a validated tool to assess disease
severity in CLE.23-25 It quantifies disease activity
(erythema, scale) and damage (dyspigmentation,
scar) over 13 distinct areas of the body. Activity
and damage scores range from 0 to 70 and 0 to 56
respectively, with higher scores representing more
severe disease. Disease activity is classified into mild
(0-9) and moderate to severe ($ 10) by CLASI
activity score.
Immunohistochemistry
Preliminary investigation into potential mediators
of PS phenotype was undertaken by examining skin
biopsy specimens from 11 patients and 5 control
subjects (age and location balanced). The goal of this
exploratory observation study was to generate,
rather than test, hypotheses; so, power analysis to
justify sample size is not presented. Punch biopsy
specimens (4 mm) were taken from sun-exposed,
extensor, nonlesion, forearm skin of patients with PS
and LE. The biopsy specimens were formalin-fixed,
paraffin-embedded, 4-mm cut sections with 3 tissue
sections placed on each slide.
After slide deparaffinization and hydration, anti-
gen retrieval was performed in Target Retrieval
Solution, high pH (S3308; DAKO Corp, Carpinteria,
CA) for 30 minutes using a water bath. Endogenous
peroxidase activity was blocked using 3% hydrogen
peroxide for 10 minutes and then protein-blocking
was performed using serum-free protein-blocking
solution (X0909; DAKO) for 1 hour. Tissue sections
were incubated overnight at 48C with either
anti-CD3 mouse monoclonal antibody (1:50, clone
LN10; Novocastra, Newcastle-upon-Tyne, United
Kingdom) or anti-CD11c rabbit monoclonal anti-
body (1:50, clone EP1347Y; ABCAM, Cambridge,
MA). Slides were then incubated at 258C for 40 min-
utes with universal biotinylated linker secondary
antibody (K0690; DAKO) for CD3 or secondary
antibody specific for rabbit primary (K4010;
DAKO) for CD11c. After, streptavidin-horseradish-
peroxidase from the Universal LSAB1 Visualization
System (DAKO) was applied to tissue sections for
30 minutes. Finally sections were developed with
freshly prepared NovoRed (Vector Laboratories,
Burlingame, CA) for 8 minutes for CD3 or with
DAB chromogen (DAKO) for 8 minutes for CD11c.
Slides were counterstained with hematoxylin. To
serve as a negative control, 1% bovine serum
I                        II                       III                            IV        V                             VI 
Always burn      Burns easily      Slowly tans       Always tans to brown           Never burns  Deeply pigmented   
(white, red hair)   (white, fair)     (white, darker)  (Mediterranean/Hispanic)  (Hispanic/black)      (dark black)
1. How much sunlight can you tolerate (with sun protection)? <30 min    Couple hours    Half day     Full day
2.    Do you avoid sun?
2a. Why?
2b. Do you wear sunscreen?
2c. Do you wear long clothes and/or hat?
2d. Do you avoid outdoors on sunny days or at peak sun 
times?
Yes        No Sometimes
Bothersome    Doctor advice   Sun damage____
Yes        No Sometimes 
Yes        No Sometimes
Yes        No Sometimes
3. Do you think your typical skin lesions get worse during summer? Yes        No ____________________
4. Does exposure to sun bring out your typical skin lesions or make 
them more severe (increased redness/itch within lesion)? Yes        No ____________________
4a. How long after sun exposure does this occur? Minutes   Later that day    Next day    Within 1 wk
4b. How long does it take to go away? Same day  Next day  Within 1 wk   Weeks to months  
5. Do you get a red or itchy or bumpy rash (not your typical skin 
lesions) when you go in sun?
Yes    No ____________________
If yes, is it?   Red    Bumpy   Itchy   ______
5a. How long after sun exposure does this occur? Minutes    Later that day    Next day    Within 1 wk
5b. How long does it take to go away? Same day  Next day  Within 1 wk   Weeks to months
5c. Which parts of your body are affected? Exposed areas         Unexposed areas 
5d. Does rash turn into typical skin lesions? Yes        No ___________________
6. In general, does your skin feel itchy when you go in sun? Yes        No ___________________
6a. How long after sun exposure does this occur? Minutes Later that day    Next day    Within 1 wk
6b. How long does it take to resolve? Same day  Next day  Within 1 wk   Weeks to months
6c. Which parts of your body are affected? Exposed areas         Unexposed areas 
7. Does your skin sting/tingle when you go in sun? Yes       No ___________________
7a. How long after sun exposure does this occur? Minutes Later that day    Next day    Within 1 wk
7b. How long does it take to resolve? Same day  Next day  Within 1 wk   Weeks to months
7c. Which parts of your body are affected? Exposed areas         Unexposed areas 
8. Do you feel weak, fatigued, or achy when you go in sun? Yes        No ____________________
Fig 1. Photosensitivity survey. Directions: Please circle the answer that best captures the
patient’s symptoms or write in an answer in the fill-in line. To indicate past or current
symptoms, please place ‘‘P’’ for past or ‘‘C’’ for current in the box.
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1 tissue section of each slide.
Cell quantification was performed for CD31
(T cells) and CD11c1 (myeloid dendritic cells
[mDC]). For each specimen, 5 consecutive fixed
fields in the papillary dermis and the reticular
dermis were photographed using 320 objective
and 310 eyepiece and Nikon microscopy camera
(Nikon, Melville, NY). Cells were counted using
ImageJ software (National Institutes of Health,
Bethesda, MD). The mean number of cells per
high-power field averaged across 10 high-power
fields (2003) was used for analyses.
Statistical analysis
For data that were assumed normally distributed,
frequencies and means 6 SD were reported.
Pearson x2 analysis was used to determine associ-
ations of gender or race with PS phenotypes.
Simple and multivariable logistic regression analy-
ses were performed to determine relationships
between PS phenotypes (dependent variable) and
CLE subtype, SLE diagnosis, SLE activity (measured
by PGA), and CLE activity (measured by CLASI
activity score). Non-gaussian response variables
were reported as frequencies and medians 6interquartile ranges. Group differences were as-
sessed by either Kruskal-Wallis or Mann-Whitney
U tests. Reported indices of association were calcu-
lated as 2-tailed P values.
RESULTS
Subject characteristics
A total of 91 subjects were enrolled with mean
age 6 SD of 46 6 13 years. Gender, race, diagnosis,
and SLE manifestations are presented in Table III.
The[ 1 CLE subtype category comprised 3 subjects
with discoid LE and subacute CLE, 3 with discoid LE
and acute CLE, 1 with tumid LE and subacute CLE,
and 1 with tumid LE and discoid LE. Of subjects, 42%
had CLE and met criteria for SLE.
Prevalence PS phenotypes in LE
Clinical interviewusing the PS survey revealed that
81% of subjects ascribed to at least 1 PS phenotype.
There were no significant (P \ .05) relationships
among gender, race, SLE diagnosis, CLE diagnosis,
PGA, CLASI activity, and the absence of PS.
Of those reporting PS (N = 74), 86% (64 of 74)
reported PS as worsening of CLE after sun exposure:
46 subjects described specific occurrences of sun-
induced CLE flare (directCLE) and 18 reported a
Table II. Timing of photosensitivity reactions
Onset Time Resolution Time
Early Within minutes
to next day
Transient Same day to
within 1 wk
Late Within 1 wk Lasting Weeks to months
Table I. Clinical photosensitivity phenotypes
Photosensitivity
phenotypes Definition
directCLE Sun-induced reaction that is specific for CLE lesions
d Develop new CLE lesions
d Increase severity or activity of existing lesions
d Increased scale, erythema, pruritus within CLE lesion
genCLE Observation that CLE is worse in summer months or that sun exposure is somehow related to CLE
flares
d Cannot describe specific incident or characteristics of how sun exposure leads to new/worsening of
CLE
genSkin PMLE-like reaction that is dissimilar to CLE skin disease
d Erythematous, papular, pruritic rash
d Generally on sun-exposed skin
d Not your typical CLE lesions
genRxn Generalized sensation of itching or stinging or burning of skin
d Affecting nonlesional skin
d No patient-observed eruption of effected skin
genSys Any sun-induced systemic symptom including not limited to: arthralgia, weakness, fatigue, headache
CLE, Cutaneous lupus erythematosus; directCLE, direct sun-induced cutaneous lupus erythematosus flare; genCLE, general exacerbation of
cutaneous lupus erythematosus; genRxn, general pruritus/paresthesias; genSys, sun-induced systemic symptoms; PMLE, polymorphic light
eruption.
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(genCLE). Of subjects, 60% (44 of 74) experienced
cutaneous reactions that were not typical for LE: 13
subjects had a PMLE-like reaction (genSkin), 12
experienced genRxn of sun-exposed skin, and 19
experienced both genSkin and genRxn (Fig 2).
Rarely did subjects experience these LE-nonspecific
cutaneous reactions in the absence of CLE-specific
PS: only 5 of 32 had genSkin and 2 of 31 genRxn
subjects reported these reactions in the absence
directCLE or genCLE phenotypes. Of subjects, 36%
(27 of 74) reported genSys and in all but 3, these
reactions co-occurred with CLE-specific (directCLE
or genCLE) and/or nonspecific cutaneous (genSkin
and/or genRxn) reactions. Of subjects reporting
genSys, 52% met criteria for SLE.
Timing of PS phenotypes
The time course of 3 PS phenotypes was investi-
gated: directCLE, genSkin, and genRxn. Of those
with directCLE, 90% experienced CLE worsening,
soon after sun exposure; half of these subjects
reported early (within 1 week) resolution, whereas
others ascribed to lasting skin reactions. Only 4 of 39subjects described late-onset sun-induced CLE-
specific skin reactions. GenSkin and genRxn groups
nearly always experienced early-onset, transient (re-
solving within 1 week) reactions to sunlight (Fig 3).
Associations among gender, race, and PS
phenotypes
Gender. Gender was significantly associated
with 2 PS phenotypes: genSkin (PMLE-like reaction,
P = .01) and genSys (P = .03) and not with any other
PS phenotype, with more female subjects than
expected reporting these phenotypes.
Race. There were no significant associations be-
tween race and any PS phenotype.
Relationships among CLE subtypes, SLE
diagnosis, CLASI activity, systemic disease
activity, and PS phenotypes
directCLE phenotype. There was a statistically
suggestive (P = .094) trend for CLASI activity scores
to predict experiencing the directCLE phenotype
with more subjects with moderate-severe compared
with mild CLASI activity experiencing directCLE after
sun exposure. Although CLE subtype, SLE diagnosis,
and systemic activity (measured by PGA) were not
significantly related to directCLE, the association
between CLASI activity and directCLE remained
statistically suggestive (P = .093) in the multivariable
model (Tables IV and V).
genCLE phenotype. In both the simple (P =
.077) and multivariable (P = .099) models, there was
a statistically suggestive trend for subjects with tumid
Table III. Subject characteristics
Characteristics N
Diagnosis
DLE 45
SCLE 21
LET 9
[1 CLE subtype 8
ACLE 5
CCLE other 3
CLE and SLE 38
Systemic manifestations in
subjects with CLE and SLE
Arthritis 14
Renal 4
Neurologic 1
Hematologic 6
Race
African American 29
Asian 7
Hispanic 2
Other 1
White 52
Gender
Male 18
Female 73
Total 91
ACLE, Acute cutaneous lupus erythematosus;CCLE, chronic cutaneous
lupus erythematosus; CLE, cutaneous lupus erythematosus; DLE,
discoid lupus erythematosus; LET, tumid lupus erythematosus; SCLE,
subacute cutaneous lupus erythematosus; SLE, systemic lupus
erythematosus.
Fig 2. Cutaneous lupus erythematosus (CLE). Percentage
of subjects with photosensitivity (PS) (N = 83) reporting
each PS phenotype as captured by PS survey. Because 23
subjects reported both genSkin and general pruritus/par-
esthesias (genRxn) concomitantly, this overlap is listed on
graph to allow for accurate percentage calculation.
directCLE, Direct sun-induced CLE flare; genCLE, general
exacerbation of CLE; genSys, sun-induced systemic
symptoms.
Fig 3. Cutaneous lupus erythematosus (CLE). Percentage
of time courses for photosensitivity (PS) reactions among
subjects experiencing direct sun-induced CLE flare
(directCLE ), genSkin, and general pruritus/paresthesias
( genRxn). Early, PS symptoms occur within minutes to
next day; lasting, PS symptoms last for weeks to months;
transient, PS symptoms resolve same day to within 1 week;
late, PS symptoms occurring from 1 day to 1 week after sun
exposure.
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a general link between CLE flares and sun exposure.
genSkin phenotype. Systemic disease activity
as measured by PGA was predictive of the genSkin
phenotypewith more subjects with PGA score of 1 or
higher (mild-severe, P = .02) experiencing PMLE-like
reactions compared with subjects with no systemic
disease activity (PGA score 0, P = .05).
genRxn phenotype. In both the simple and
multivariable model, SLE diagnosis was predictive
of the genRxn phenotype such that subjects with
both SLE and CLE were more likely (P = .003) to
experience PMLE-like reactions compared with
those with CLE alone (P = .04). PGA scores were
predictive of genRxn in the simple model, but
failed to reach significance in the multivariable
analysis.
genSys phenotype. Sun-induced systemic reac-
tions (genSys) were predicted by PGA scores in the
simple model (P = .021) and trended toward predic-
tive in the multivariable model (P = .064), such that
subjectswithmore active systemic disease (PGA score
$ 1) experienced the genSys phenotype, whereas
those with no systemic activity (PGA score 0) did not.Immunohistochemistry
Immunohistochemistry for mDC and T cells was
conducted using anti-CD11c and anti-CD3 monoclo-
nal antibody, respectively. The Mann-Whitney test
indicated a significant difference in mDC (CD11c)
counts between subjects with versus those without
genSys (P = .04) and a statistically suggestive trend
(P = .06) toward subjects with systemic symptoms
having more resident (CD3) T cells (Fig 4). There
Table IV. P values for simple logistic regression
analyses with photosensitivity phenotypes as
dependent variables
PS phenotypes CLE subtype* SLE diagnosisy PGAz CLASIx
directCLE .438 .971 .542 .094
genCLE .077 .831 .398 .949
genSkin .843 .356 .017 .488
genRxn .098 .003 .051 .712
genSys .359 .135 .021 .754
CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity
Index; CLE, cutaneous lupus erythematosus; directCLE, direct sun-
induced cutaneous lupus erythematosus flare; genCLE, general
exacerbation of cutaneous lupus erythematosus; genRxn, general
pruritus/paresthesias; genSys, sun-induced systemic symptoms;
PGA, Physicians Global Assessment; PS, photosensitivity; SLE,
systemic lupus erythematosus.
*Discoid lupus erythematosus, subacute CLE, acute CLE, tumid
lupus erythematosus, chronic CLE other,[1 CLE subtype.
yCLE alone vs CLE and SLE.
zSystemic activity (score 0 none vs $ 1 mild-severe).
xCutaneous activity (\9 mild vs $ 10 moderate-severe).
Table V. P values for multivariable logistic
regression analyses with photosensitivity
phenotypes as dependent variables
PS phenotypes CLE subtype* SLE diagnosisy PGAz CLASIx
directCLE .454 .331 .695 .093
genCLE .099 .229 .499 .994
genSkin .755 .740 .051 .227
genRxn .367 .042 .125 .707
genSys .511 .619 .064 .419
CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity
Index; CLE, cutaneous lupus erythematosus; directCLE, direct
sun-induced cutaneous lupus erythematosus flare; genCLE,
general exacerbation of CLE; genRxn, general pruritus/
paresthesias; genSys, sun-induced systemic symptoms; PGA,
Physicians Global Assessment; PS, photosensitivity; SLE, systemic
lupus erythematosus.
*Discoid lupus erythematosus, subacute CLE, acute CLE, tumid
lupus erythematosus, chronic CLE other,[1 CLE subtype.
yCLE alone vs CLE and SLE.
zSystemic activity (score 0 none vs $ 1 mild-severe).
xCutaneous activity (\9 mild vs $ 10 moderate-severe).
Fig 4. Cutaneous lupus erythematosus (LE). Median
(6 interquartile range) of cell counts for myeloid dendritic
cells (CD11c1) and T cells (CD31) in dermis of patients
with LE who are photosensitive with and without sun-
induced systemic symptoms (genSys) and in age- and skin
typeematched control subjects. Mann-Whitney tests of cell
counts of subjects with versus without genSys; *P = .04,
#P = .06. hpf, High-power field.
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SLE diagnosis; nor were there significant differences
in mDC or T-cell counts between subjects with and
without SLE. Subjects with genSys tended to have
lower CLASI activity scores compared with subjects
denying genSys (median 6 interquartile range: 5 6
12 vs 16 6 13) and SLEDAI scores were not
significantly different.
DISCUSSION
Clinical interviews using the PS survey allowed us
to carefully characterize self-reported PS among aprimarily CLE population. There was tremendous
variability in how patients with LE experience PS.
Overall, we found that 81% of subjects report PS.
Unlike previous reports suggesting that PS occurs
more commonly in whites compared with other
racial groups, we found no associations between
any PS phenotype and race.1,26,27
Not surprisingly, most PS reactions fell in the
CLE-specific category. The most common PS pheno-
type was directCLE with 62% of PS subjects reporting
specific examples of sun-induced CLE flare. In con-
trast to reports describing a delay between sun
exposure and CLE induction, the majority of subjects
reported sun-induced CLE flares occurring early after
sun exposure.4 Exacerbations were commonly de-
scribed to be transient as opposed to lasting (for
weeks tomonths). Interestingly, therewas a trend for
subjects with higher CLASI activity scores to report
directCLE phenotype. We have shown previously
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PS in LE.20 It would be interesting to investigate
whether patients with more active CLE disease have
a greater degree of PS or whether sun-induced
reactions lead to more active CLE disease.
CLE-nonspecific PS reactions were related to
systemic disease activity and SLE diagnosis. More
active systemic disease (as measured by PGA) but
not SLE diagnosis predicted PMLE-like reactions
and systemic reactions, whereas SLE diagnosis and
PGA predicted the genRxn phenotype of pruritus/
paresthesia. Although these reactions nearly always
occurred in association with a CLE-specific pheno-
type (ie, directCLE or genCLE), experiencing a non-
specific cutaneous reaction to sunlight may suggest
more active systemic disease.
A PMLE-like reaction was reported by 43% of
patients, which is consistent with prior reports that
suggest an increased prevalence of this form of
eruption in patients with LE, compared with the
general population.13,14 These reactions, however,
often occurred immediately after sun exposure,
resolved within 1 day, and rarely occurred in the
absence of CLE-specific PS reactions. Because these
reactions differ from PMLE in timing and setting,
these findings suggest that PMLE-like reactions may
occur as part of a PS spectrum in LE16 rather than
PMLE as a co-occurring disorder.28,29
Over one third of patients reported systemic
reactions to sunlight; only 50% met criteria for SLE
and analysis indicated that higher PGA scores were
predictive of the genSys phenotype. Furthermore,
immunohistochemical analysis of sun-exposed skin
of a subset of patients with genSys was associated
with an increased number of mDC and a trend
toward more T cells compared with patients who
had PS without genSys. Skin resident T-cell andmDC
populations have been described recently,30,31 and
greater prevalence of immunologically active cells
was found resident in the skin of patients with CLE
and SLE features. These results highlight the com-
plexity of ultraviolet radiation effects in LE and
suggest that resident inflammatory cells in the skin
may play a role in systemic reactions of PS in LE.
This study had several limitations. First, study
participants were treated at the autoimmune skin
disease clinic of the University of Pennsylvania,
which is a referral-only center. Second, PS reactions
were inferred and were not directly observed. Third,
study staff made every effort to use open-ended
questions in the clinical interview pertaining to PS to
minimize patient recall bias, however, some element
of recall bias is likely present, which could artificially
inflate the prevalence of PS phenotypes in the
sample. Further, data collection occurred acrossseasons, which may contribute to recall bias.
Finally, investigation of the pathomechanism of
self-reported PS was hypothesis-generating in na-
ture. With only a small number of subject biopsy
specimens for immunohistochemistry, our analyses
were not powered to detect differences that might
truly exist in resident cell populations among the
various cutaneous PS phenotypes or specific CLE
diagnoses.
CONCLUSION
Characterization of self-reported PS in LE reveals
that patients experience combinations of CLE-
specific, CLE-nonspecific, and systemic reactions to
sunlight. Sun-induced CLE flares are associated with
more active CLE disease. PMLE-like, generalized
pruritus/paresthesia, and systemic reactions are as-
sociated with more active systemic disease regard-
less of SLE diagnosis. Although the pathomechanism
of these varied PS phenotypes is far from under-
stood, these data suggest that resident immune cells
in the skin might contribute to both SLE and CLE
activity. Future studies, examining immunologically
active cells in nonlesional skin both before and after
ultraviolet radiation exposure, could help elucidate
the contribution of resident skin cells on various PS
phenotypes and explain how PS contributes to both
CLE-specific and systemic disease activity.
REFERENCES
1. Scheinfeld N, Deleo VA. Photosensitivity in lupus erythemato-
sus. Photodermatol Photoimmunol Photomed 2004;20:272-9.
2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF,
et al. The 1982 revised criteria for the classification of systemic
lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
3. Kind P, Lehmann P, Plewig G. Phototesting in lupus eryth-
ematosus. J Invest Dermatol 1993;100:53S-7S.
4. Kuhn A, Sonntag M, Richter-Hintz D, Oslislo C, Megahed M,
Ruzicka T, et al. Phototesting in lupus erythematosus: a
15-year experience. J Am Acad Dermatol 2001;45:86-95.
5. Schornagel IJ, Knol EF, van Weelden H, Guikers CL, Bruijn-
zeel-Koomen CA, Sigurdsson V. Diagnostic phototesting in
polymorphous light eruption: the optimal number of irradia-
tions. Br J Dermatol 2005;153:1234-6.
6. Lokitz ML, Billet S, Patel P, Kwon EJ, Sayre RM, Sullivan KE, et al.
Failure of physiologic doses of pure UVA or UVB to induce
lesions in photosensitive cutaneous lupus erythematosus:
implications for phototesting. Photodermatol Photoimmunol
Photomed 2006;22:290-6.
7. Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC,
et al. The quality of life of 790 patients with photodermatoses.
Br J Dermatol 2008;159:192-7.
8. Morison WL. Clinical practice. photosensitivity. N Engl J Med
2004;350:1111-7.
9. Millard TP, Hawk JL. Photosensitivity disorders: cause, effect
and management. Am J Clin Dermatol 2002;3:239-46.
10. Pincus LB, LeBoit PE, Goddard DS, Cho RJ, McCalmont TH.
Marked papillary dermal edemaean unreliable discriminator
between polymorphous light eruption and lupus erythema-
tosus or dermatomyositis. J Cutan Pathol 2010;37:416-25.
J AM ACAD DERMATOL
VOLUME 69, NUMBER 2
Foering et al 21311. Epstein JH. Polymorphous light eruption. Dermatol Clin 1986;
4:243-51.
12. Holzle E, Plewig G, von Kries R, Lehmann P. Polymorphous
light eruption. J Invest Dermatol 1987;88(Suppl):32S-8S.
13. Hasan T, Nyberg F, Stephansson E, Puska P, Hakkinen M, Sarna
S, et al. Photosensitivity in lupus erythematosus, UV photo-
provocation results compared with history of photosensitivity
and clinical findings. Br J Dermatol 1997;136:699-705.
14. Nyberg F, Hasan T, Puska P, Stephansson E, Hakkinen M, Ranki
A, et al. Occurrence of polymorphous light eruption in lupus
erythematosus. Br J Dermatol 1997;136:217-21.
15. Gronhagen C, Gunnarsson I, Svenungsson E, Nyberg F. Cuta-
neous manifestations and serological findings in 260 patients
with systemic lupus erythematosus. Lupus 2010;19:1187-94.
16. Tzaneva S, Volc-Platzer B, Kittler H, H€onigsmann H, Tanew A.
Antinuclear antibodies in patients with polymorphic light
eruption: a long-term follow-up study. Br J Dermatol 2008;158:
1050-4.
17. Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K,
Martin-Villalba A, et al. Accumulation of apoptotic cells in the
epidermis of patients with cutaneous lupus erythematosus
after ultraviolet irradiation. Arthritis Rheum 2006;54:939-50.
18. Hasan T, Ranki A, Jansen CT, Karvonen J. Disease associations
in polymorphous light eruption: a long-term follow-up study
of 94 patients. Arch Dermatol 1998;134:1081-5.
19. Hasan T, Stephansson E, Ranki A. Distribution of naive and
memory T-cells in photoprovoked and spontaneous skin
lesions of discoid lupus erythematosus and polymorphous
light eruption. Acta Derm Venereol 1999;79:437-42.
20. Foering K, Okawa J, Rose M, Goreshi R, LoMonico J, Werth V.
Characterization of photosensitivity and poor quality of life in
lupus. J Invest Dermatol 2010;130(Suppl):S10.
21. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in
the spectrum of lupus erythematosus. J Am Acad Dermatol
1981;4:471-5.
22. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn
BH, et al. The effect of combined estrogen and progesteronehormone replacement therapy on disease activity in systemic
lupus erythematosus: a randomized trial. Ann Intern Med
2005;142:953-62.
23. Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E,
Kolasinski SL, et al. The cutaneous lupus erythematosus
disease activity and severity index: expansion for rheumatol-
ogy and dermatology. Arthritis Rheum 2008;59:338-44.
24. Bonilla-Martinez ZL, Albrecht J, Troxel AB, Taylor L, Okawa J,
Dulay S, et al. The cutaneous lupus erythematosus disease
area and severity index: a responsive instrument to measure
activity and damage in patients with cutaneous lupus
erythematosus. Arch Dermatol 2008;144:173-80.
25. Albrecht J, Werth VP. Development of the CLASI as an
outcome instrument for cutaneous lupus erythematosus.
Dermatol Ther 2007;20:93-101.
26. Smikle MF, Barton EN, Morgan OS, Deceulaer K. Photosensi-
tivity and antinuclear antibodies in black patients with sys-
temic lupus erythematosus. J Assoc Acad Minor Phys 1996;7:
53-5.
27. Ward MM, Studenski S. Clinical manifestations of systemic
lupus erythematosus: identification of racial and socioeco-
nomic influences. Arch Intern Med 1990;150:849-53.
28. Millard TP, Lewis CM, Khamashta MA, Hughes GR, Hawk JL,
McGregor JM. Familial clustering of polymorphic light erup-
tion in relatives of patients with lupus erythematosus: evi-
dence of a shared pathogenesis. Br J Dermatol 2001;144:
334-8.
29. Millard TP, Kondeatis E, Vaughan RW, Lewis CM, Khamashta
MA, Hughes GR, et al. Polymorphic light eruption and the
HLA DRB1*0301 extended haplotype are independent risk
factors for cutaneous lupus erythematosus. Lupus 2001;10:
473-9.
30. Clark RA. Skin-resident T cells: the ups and downs of on site
immunity. J Invest Dermatol 2010;130:362-70.
31. Zaba LC, Krueger JG, Lowes MA. Resident and ‘‘inflammatory’’
dendritic cells in human skin. J Invest Dermatol 2009;129:
302-8.
